Oxagen Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.oxagen.co.uk
FDA Approves DUPIXENT for Pediatric Eosinophilic Esophagitis, Expanding Treatment Options
The FDA has granted approval for DUPIXENT (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged 1-11 years weighing at least 15 kg. The approval follows successful Phase III EoE KIDS trial results showing superior histological remission rates compared to placebo. This development represents a significant advancement in treating pediatric EoE, a condition affecting approximately 1 in 2,000 people.
© Copyright 2025. All Rights Reserved by MedPath